Phase II trial of temozolomide in patients with cisplatin-refractory germ cell tumors

被引：10
|
作者：
Kondagunta, GV
Bacik, J
Schwartz, L
Sheinfeld, J
Bajorin, D
Vuky, J
Marion, S
Mazumdar, M
Bosl, GJ
Motzer, RJ
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Urol, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Biostat Epidemiol & Stat, New York, NY 10021 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2004年 / 22卷 / 02期
关键词：
temozolomide; germ cell tumor; nonseminoma; cisplatin-refractory; phase II;
D O I：
10.1023/B:DRUG.0000011794.21608.59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Fourteen patients with cisplatin-refractory germ cell tumors (GCT) were treated with temozolomide on a phase II trial. Temozolomide was given orally at 150 mg/m(2)/day on days 1-5. The cycle length was 28 days. No patient experienced a grade 3 or 4 toxicity, and none of the 14 evaluable patients achieved a complete or partial response. Temozolomide is not efficacious in the treatment of cisplatin-refractory GCT patients.
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [31] Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors
    Perez Segura, Pedro
    Gil, Miguel
    Balana, Carmen
    Chacon, Ignacio
    Munoz Langa, Jose
    Martin, Maria
    Bruna, Jordi
    JOURNAL OF NEURO-ONCOLOGY, 2012, 109 (01) : 137 - 142
  • [32] A phase II trial of VP-16, ifosfamide, cisplatin, vinblastine, and bleomycin in advanced germ-cell tumors
    Blanke, C
    Loehrer, PJ
    Nichols, CR
    Einhorn, LH
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (05): : 487 - 491
  • [33] Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients
    Silvani, A
    Eoli, M
    Salmaggi, A
    Lamperti, E
    Maccagnano, E
    Broggi, G
    Boiardi, A
    JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) : 203 - 208
  • [34] Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors
    Xiang, Jenny J.
    Campbell, Matthew T.
    Tu, Shi-Ming
    Araujo, John
    Nieto, Yago
    Lin, John K.
    Xiao, Lianchun
    Shah, Amishi Y.
    Wang, Jianbo
    CLINICAL GENITOURINARY CANCER, 2024, 22 (06)
  • [35] Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients
    Antonio Silvani
    Marica Eoli
    Andrea Salmaggi
    Elena Lamperti
    Elio Maccagnano
    Giovanni Broggi
    Amerigo Boiardi
    Journal of Neuro-Oncology, 2004, 66 : 203 - 208
  • [36] A phase II trial of primary temozolomide in patients with grade III oligodendroglial brain tumors
    Gan, Hui K.
    Rosenthal, Mark A.
    Dowling, Anthony
    Kalnins, Renate
    Algar, Elizabeth
    Wong, Nicholas
    Benson, Angela
    Woods, Anne-Marie
    Cher, Lawrence
    NEURO-ONCOLOGY, 2010, 12 (05) : 500 - 507
  • [37] Hyperthermia for the treatment of patients with malignant germ cell tumors -: a phase I/II study in ten children and adolescents with recurrent or refractory tumors
    Wessalowski, R
    Kruck, H
    Pape, H
    Kahn, T
    Willers, R
    Göbel, U
    CANCER, 1998, 82 (04) : 793 - 800
  • [38] Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study
    Oechsle, K.
    Honecker, F.
    Cheng, T.
    Mayer, F.
    Czaykowski, P.
    Winquist, E.
    Wood, L.
    Fenner, M.
    Glaesener, S.
    Hartmann, J. T.
    Chi, K.
    Bokemeyer, C.
    Kollmannsberger, C.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2654 - 2660
  • [39] Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT
    Einhorn, LH
    Brames, MJ
    Heinrich, MC
    Corless, CL
    Madani, A
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (01): : 12 - 13
  • [40] Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial
    Fizazi, K.
    Gravis, G.
    Flechon, A.
    Geoffrois, L.
    Chevreau, C.
    Laguerre, B.
    Delva, R.
    Eymard, J. C.
    Rolland, F.
    Houede, N.
    Laplanche, A.
    Burcoveanu, D.
    Culine, S.
    ANNALS OF ONCOLOGY, 2014, 25 (05) : 987 - 991
12345